

CALDON BIOTECH INC.
ScI-70 Autoantibody
ELISA

Catalog No. SC043G
(96 tests)

NAME AND INTENDED USE

The CALDON BIOTECH INC (CBI), ScI-70 IgG ELISA is intended for use in the evaluation of patients with suspected autoimmune diseases.

SUMMARY AND EXPLANATION OF THE TEST

Systemic autoimmune disease is characterized by the presence of circulating auto-antibodies directed to a wide variety of cellular antigens. Systemic lupus erythematosus (SLE), commonly referred to as Lupus is the best known of these diseases. Other possible connective tissue diseases include mixed connective tissue disease (MCTD), Sjogren syndrome, scleroderma, and polymyositis/dermatomyositis. The majority can be diagnosed by clinical presentation and their antibody profiles to the various antigens involved, which include dsDNA, SM, RNP, SSA, SSB ScI-70, Jo1 and Histones. Therefore, immunoassays for autoantibodies are useful for diagnostic and prognostic evaluations of autoimmune disease. ScI-70 IgG antibodies react with human topoisomerase I of 100 kd molecular weight as well as its 70 kd fragment. ScI-70 antibodies are present in 20-40% of diffuse scleroderma patients and in about 20% of patients with limited scleroderma. ScI-70 antibodies are sometimes reported in classical SLE without features of scleroderma, which may explain the unexpected co-existence of marker autoantibodies for SLE and scleroderma. Some patients with silica-associated systemic sclerosis (SSc) have ScI-70 antibodies.

PRINCIPLE OF THE TEST

Diluted patient serum is added to wells coated with purified antigen. IgG specific antibody, if present, binds to the antigen. All unbound materials are washed away and the enzyme conjugate is added to bind to the antibody-antigen complex, if present. Excess enzyme conjugate is washed off and substrate is added. The plate is incubated to allow the hydrolysis of the substrate by the enzyme. The intensity of the color generated is proportional to the amount of IgG specific antibody in the sample.

MATERIALS PROVIDED

- Microwell Strips: ScI-70 antigen coated wells (12 x 8 x 1 wells)
- Sample Diluent: 1 bottle (22 mL). Ready to use.
- Calibrator: Yellow Cap. (1.50 mL/vial). Ready to use.
- Positive Control: Red Cap. (1.50 mL/vial). Ready to use.
- Negative Control: Blue Cap. (1.50 mL/vial). Ready to use.
- Enzyme Conjugate: 1 bottle (12 mL). Ready to use.
- TMB Substrate: 1 bottle (12 mL). Ready to use.
- Stop Solution: 1N H₂SO₄; 1 bottle (12 mL). Ready to use.
- Wash Concentrate: 1 bottle (50 mL), 20X concentrate.

STORAGE AND STABILITY

- Store the kit at 2-8°C.
- Keep microwells sealed in a dry bag with desiccants.
- The reagents are stable until expiration of the kit.
- Do not expose test reagents to heat, sun or strong light during storage or usage.

WARNINGS AND PRECAUTIONS

1. Potential biohazardous materials:
The calibrator and controls contain human source components which have been tested and found non-reactive for hepatitis B surface antigen as well as HIV antibody with FDA licensed reagents. However, there is no test method that can offer complete assurance that HIV, Hepatitis B virus or other infectious agents are absent. These reagents should be handled at the Biosafety Level 2, as recommended in the Centers for Disease Control/National Institutes of Health manual, "Biosafety in Microbiological and Biomedical Laboratories." 1984.
2. Optimal results will be obtained by strict adherence to the test protocol. Precise pipetting as well as following the exact time and temperature requirements is essential.
3. Do not pipette by mouth. Do not smoke, eat, or drink in the areas in which specimens or kit reagents are handled.
4. The components in this kit are intended for use as an integral unit. The components of different lots should not be mixed.
5. Control sera and sample diluent contain preserved with sodium azide. Sodium azide may react with lead and copper plumbing to form explosive metal azide. On disposal, flush with a large volume of water.

SPECIMEN COLLECTION AND HANDLING

1. Collect blood specimens and separate the serum.
2. Specimens may be refrigerated at 2–8°C for up to seven days or frozen for up to six months. Avoid repetitive freezing and thawing of samples.

PREPARATION FOR ASSAY

1. Bring all specimens and kit reagents to room temperature (20–25°C) and gently mix.
2. Prepare washing buffer by adding the contents of the bottle (50 mL, 20X Wash concentrate) to 950 mL of distilled or deionized water in one-liter container. Store at room temperature.

ASSAY PROCEDURE

1. Place the desired number of coated strips into the holder.

2. Negative control, positive control, and calibrator are ready to use.

Prepare 1:21 dilution of test samples, by adding 10 µL of the sample to 200 µL of sample diluent. Mix well.

3. Dispense 100 µL of diluted sera, calibrator and controls into the appropriate wells. For the reagent blank, dispense 100 µL sample diluent in 1A well position. Tap the holder to remove air bubbles from the liquid and mix well. Incubate for 20 minutes at room temperature.
4. Remove liquid from all wells. Repeat washing three times with wash buffer.
5. Dispense 100 µL of enzyme conjugate to each well and incubate for 20 minutes at room temperature.
6. Remove enzyme conjugate from all wells. Repeat washing three times with wash buffer.
7. Dispense 100 µL of TMB substrate solution and incubate for 10 minutes at room temperature.
8. Add 100 µL of 1N H₂SO₄ to stop reaction.
9. Read O.D. within 30 min at 450 nm using microwell reader.

CALCULATION OF RESULTS

1. Check Calibrator Factor (CF) value on the calibrator bottle. This value might vary from lot to lot. Make sure you check the value on every kit.
2. Calculate the cut-off value: Calibrator OD x Calibrator Factor (CF).
3. Calculate the Ab (Antibody) Index of each determination by dividing the O.D. value of each sample by cut-off value.

Example of typical results:

Calibrator mean OD = 0.8
 Calibrator Factor (CF) = 0.5
 Cut-off Value = 0.8 x 0.5 = 0.400
 Positive control O.D. = 1.2
 Ab Index = 1.2 / 0.4 = 3

Patient sample O.D. = 1.6
 Ab Index = 1.6 / 0.4 = 4.0

QUALITY CONTROL

The test run may be considered valid provided the following criteria are met:

- The O.D. of the Calibrator should be greater than 0.250.
- The Ab index for Negative control should be less than 0.9.
- The Ab Index for Positive control should be greater than 1.2.

INTERPRETATION

The following is intended as a guide to interpretation of test results; each laboratory is encouraged to establish its own criteria for test interpretation based on sample populations encountered.

Antibody Index Interpretation

<0.9 No detectable antibody to Scl-70 by ELISA.
 0.9-1.1 Borderline positive. Follow-up testing is recommend if clinically indicated.
 >1.1 Indicative of Autoimmune diseases.

LIMITATIONS OF THE TEST

1. The test results obtained using this kit serve only as an aid to diagnosis and should be interpreted in relation to the patient's history, physical findings and other diagnostic procedures.
2. Lipemic or hemolyzed samples may cause erroneous results.

PERFORMANCE CHARACTERISTICS**1. Sensitivity and Specificity**

122 patient sera were tested by this Scl-70 IgG ELISA and a reference ELISA method. 14 sera were positive and 103 were negative by both methods (95% agreement).

The results are summarized below:

	Scl-70 IgG ELISA		
	+	-	Total
Reference ELISA	14	2	
+ Kit	16	3	103
- Kit	106		
Total	17	105	122

2. Precision

Intra-Assay Study

Serum	No. of Replicates	Mean	Standard Deviation	Coefficient of Variation%
1	16	1.32	0.084	6.3
2	16	0.69	0.051	7.4
3	16	0.18	0.016	8.8

enzyme-linked immunosorbent assay. Arthritis Rheum 1988;31:108-15.
oct-00

Inter-Assay Study

Serum	No. of Replicates	Mean	Standard Deviation	Coefficient of Variation%
1	10	1.51	0.121	8.0
2	10	0.74	0.081	10.9
3	10	0.21	0.024	11.4

REFERENCES

- Hildebrandt S, Weiner ES, Senecal J-L, Noell GS, Earnshaw WC, Rothfield NF. Autoantibodies to topoisomerase I (Scl-70): analysis by gel diffusion, immunoblot, and enzyme-linked immunosorbent assay. Clin Immunol Immunopathol 1990;57:399-410.
- Hildebrandt S, Weiner E, Senecal J, et al. The IgG, IgM, and IgA isotypes of anti-topoisomerase I and anticentromere autoantibodies. Arthritis Rheum 1990;33:724-7.
- Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988;31:196-203.
- Hildebrandt S, Jäckh G, Weber S, Peter H-H. A long-term longitudinal isotypic study of anti-topoisomerase I autoantibodies. Rheumatol Int 1993;12:321-4.
- Briggs DC, Vaughan RW, Welsh KI, Myers A, DuBois RM, Black CM. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991;338:661-2.
- Mukai M, Sagawa A, Atsumi T, et al. 3 cases of anti-Scl-70 (topoisomerase I) antibody associated with central nervous system lupus without renal disorder. J Rheumatol 1993;20:91594-7.
- Stojanov L, Satoh M, Dooley MA, Kuwana M, Jennette JC, Reeves WH. Autoantibodies to topoisomerase I in a patient with systemic lupus erythematosus without features of scleroderma. Lupus 1995;4:314-7.
- Juarez C, Vila JL, Gelpi C, et al. Characterization of the antigen reactive with anti-Scl-70 antibodies and its application in an